ISCOMATRIX vaccines mediate CD8 T-cell cross-priming by a MyD88-dependent signaling pathway

Immunology and Cell Biology

Volumn 90, Issue 5, 2012, Pages 540-552

  Wilson, Nicholas S ^a   Yang, Becky ^a   Morelli, Adriana Baz ^b   Koernig, Sandra ^b   Yang, Annie ^a   Loeser, Stefanie ^a   Airey, Denise ^b   Provan, Larissa ^b   Hass, Phil ^a   Braley, Hal ^b   Couto, Suzana ^a   Drane, Debbie ^b   Boyle, Jeff ^b   Belz, Gabrielle T ^c   Ashkenazi, Avi ^a   Maraskovsky, Eugene ^b  

^a GENENTECH INC   (United States)

^b CSL LIMITED   (Australia)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

cross presentation; CTL; ISCOMATRIX; MyD88; tumor; vaccines

Indexed keywords

ANTINEOPLASTIC AGENT; CD40 ANTIGEN; CD8ALPHA ANTIGEN; IMMUNOMODULATING AGENT; ISCOMATRIX; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MYELOID DIFFERENTIATION FACTOR 88; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER THERAPY; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELLULAR IMMUNITY; CLINICAL DEVELOPMENT PLAN; CONTROLLED STUDY; CROSS PRESENTATION; DENDRITIC CELL; HUMAN; IMMUNOCOMPETENT CELL; IN VIVO STUDY; INNATE IMMUNITY; LYMPH NODE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; WNT SIGNALING PATHWAY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CHOLESTEROL; CROSS-PRIMING; DENDRITIC CELLS; DRUG COMBINATIONS; HUMANS; KILLER CELLS, NATURAL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MYELOID DIFFERENTIATION FACTOR 88; OVALBUMIN; PHOSPHOLIPIDS; RECEPTOR CROSS-TALK; SAPONINS; SIGNAL TRANSDUCTION;

EID: 84861661926     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2011.71     Document Type: Article

References (60)

1. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15: 5323-5337.
2. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-915.
3. Lake RA, Robinson BW. Immunotherapy and chemotherapy-a practical partnership. Nat Rev Cancer 2005; 5: 397-405.
4. Heath WR, Belz GT, Behrens GM, Smith CM, Forehan SP, Parish IA et al. Crosspresentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 2004; 199: 9-26.
5. Tritto E, Mosca F, De Gregorio E. Mechanism of action of licensed vaccine adjuvants. Vaccine 2009; 27: 3331-3334.
6. Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009; 30: 23-32.
7. Drane D, Gittleson C, Boyle J, Maraskovsky E. ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines. Expert Rev Vaccines 2007; 6: 761-772.
8. Maraskovsky E, Schnurr M, Wilson NS, Robson NC, Boyle J, Drane D. Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant. Immunol Cell Biol 2009; 87: 371-376.
9. Wilson NS, Villadangos JA. Regulation of antigen presentation and cross-presentation in the dendritic cell network: facts, hypothesis, and immunological implications. Adv Immunol 2005; 86: 241-305.
10. Smith CM, Belz GT, Wilson NS, Villadangos JA, Shortman K, Carbone FR et al. Cutting edge: conventional CD8 alpha+ dendritic cells are preferentially involved in CTL priming after footpad infection with herpes simplex virus-1. J Immunol 2003; 170: 4437-4440.
11. Schnorrer P, Behrens GM, Wilson NS, Pooley JL, Smith CM, El-Sukkari D et al. The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture. Proc Natl Acad Sci U S A 2006; 103: 10729-10734.
12. Belz GT, Smith CM, Eichner D, Shortman K, Karupiah G, Carbone FR et al. Cutting edge: conventional CD8 alpha+ dendritic cells are generally involved in priming CTL immunity to viruses. J Immunol 2004; 172: 1996-2000.
13. Wilson NS, Behrens GM, Lundie RJ, Smith CM, Waithman J, Young L et al. Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat Immunol 2006; 7: 165-172.
14. Belz GT, Bedoui S, Kupresanin F, Carbone FR, Heath WR. Minimal activation of memory CD8+ T cell by tissue-derived dendritic cells favors the stimulation of naive CD8+ T cells. Nat Immunol 2007; 8: 1060-1066.
15. Bedoui S, Whitney PG, Waithman J, Eidsmo L, Wakim L, Caminschi I et al. Crosspresentation of viral and self antigens by skin-derived CD103+ dendritic cells. Nat Immunol 2009; 10: 488-495.
16. Akira S, Takeda K. Toll-like receptor signaling. Nat Rev Immunol 2004; 4: 499-511.
17. Lamkanfi M, Dixit VM. Inflammasomes: guardians of cytosolic sanctity. Immunol Rev 2009; 227: 95-105.
18. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25: 267-296.
19. Cao X. Regulatory T cells and immune tolerance to tumors. Immunol Res 2009; 46: 79-93.
20. Edwards JC, Sedgwick AD, Willoughby DA. The formation of a structure with the features of synovial lining by subcutaneous injection of air: an in vivo tissue culture system. J Pathol 1981; 134: 147-156.
21. Smith CM, Wilson NS, Waithman J, Villadangos JA, Carbone FR, Heath WR et al. Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nat Immunol 2004; 5: 1143-1148.
22. Bevan MJ. Helping the CD8(+) T-cell response. Nat Rev Immunol 2004; 4: 595-602.
23. Cosgrove D, Gray D, Dierich A, Kaufman J, Lemeur M, Benoist C et al. Mice lacking MHC class II molecules. Cell 1991; 66: 1051-1066.
24. Ramirez-Montagut T, Chow A, Hirschhorn-Cymerman D, Terwey TH, Kochman AA, Lu S et al. Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J Immunol 2006; 176: 6434-6442.
25. French RR, Chan HT, Tutt AL, Glennie MJ. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 1999; 5: 548-553.
26. van Mierlo GJ, den Boer AT, Medema JP, van der Voort EI, Fransen MF, Offringa R et al. CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci U S A 2002; 99: 5561-5566.
27. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
28. Walzer T, Dalod M, Robbins SH, Zitvogel L, Vivier E. Natural-killer cells and dendritic cells: 'l'union fait la force'. Blood 2005; 106: 2252-2258.
29. Jung S, Unutmaz D, Wong P, Sano G, De los Santos K, Sparwasser T et al. In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell-associated antigens. Immunity 2002; 17: 211-220.
30. Allan RS, Smith CM, Belz GT, van Lint AL, Wakim LM, Heath WR et al. Epidermal viral immunity induced by CD8alpha+ dendritic cells but not by Langerhans cells. Science 2003; 301: 1925-1928.
31. Merad M, Sugie T, Engleman EG, Fong L. In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood 2002; 99: 1676-1682.
32. De Smedt T, Pajak B, Muraille E, Lespagnard L, Heinen E, De Baetselier P et al. Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J Exp Med 1996; 184: 1413-1424.
33. Naik SH, Proietto AI, Wilson NS, Dakic A, Schnorrer P, Fuchsberger M et al. Cutting edge: generation of splenic CD8+ and CD8-dendritic cell equivalents in Fms-like tyrosine kinase 3 ligand bone marrow cultures. J Immunol 2005; 174: 6592-6597.
34. Brasel K, De Smedt T, Smith JL, Maliszewski CR. Generation of murine dendritic cells from flt3-ligand-supplemented bone marrow cultures. Blood 2000; 96: 3029-3039.
35. Reis e Sousa C. Activation of dendritic cells: translating innate into adaptive immunity. Curr Opin Immunol 2004; 16: 21-25.
36. Metcalfe SM. LIF in the regulation of T-cell fate and as a potential therapeutic. Genes Immun 2011; 12: 157-168.
37. Schnurr M, Orban M, Robson NC, Shin A, Braley H, Airey D et al. ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II. J Immunol 2009; 182: 1253-1259.
38. Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 2005; 11(Suppl 4): S63-S68.
39. Fifis T, Gamvrellis A, Crimeen-Irwin B, Pietersz GA, Li J, Mottram PL et al. Sizedependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol 2004; 173: 3148-3154.
40. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science 2010; 327: 656-661.
41. Rethinking therapeutic cancer vaccines. Nat Rev 2009; 8: 685-686.
42. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8: 59-73.
43. Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010; 18: 160-170.
44. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al. Improved Survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
45. Morse MA, Whelan M. A year of successful cancer vaccines points to a path forward. Curr Opin Mol Ther 2010; 12: 11-13.
46. Jacobs C, Duewell P, Heckelsmiller K, Wei J, Bauernfeind F, Ellermeier J et al. An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma. Int J Cancer 2011; 128: 897-907.
47. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signaling. Nature 1998; 393: 478-480.
48. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998; 393: 474-478.
49. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011; 331: 1612-1616.
50. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11: 373-384.
51. Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, Sakagami M et al. Targeted disruption of the MyD88 gene results in loss of IL-1-and IL-18-mediated function. Immunity 1998; 9: 143-150.
52. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H et al. Role of adapter TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003; 301: 640-643.
53. Wilson NS, El-Sukkari D, Belz GT, Smith CM, Steptoe RJ, Heath WR et al. Most lymphoid organ dendritic cell types are phenotypically and functionally immature. Blood 2003; 102: 2187-2194.
54. Maraskovsky E, Sjolander S, Drane DP, Schnurr M, Le TT, Mateo L et al. NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors. Clin Cancer Res 2004; 10: 2879-2890.
55. Watanabe J, Miyazaki Y, Zimmerman GA, Albertine KH, McIntyre TM. Endotoxin contamination of ovalbumin suppresses murine immunologic responses and development of airway hyper-reactivity. J Biol Chem 2003; 278: 42361-42368.
56. Lenarczyk A, Le TT, Drane D, Malliaros J, Pearse M, Hamilton R et al. ISCOM based vaccines for cancer immunotherapy. Vaccine 2004; 22: 963-974.
57. Sun JC, Bevan MJ. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 2003; 300: 339-342.
58. Sapoznikov A, Jung S. Probing in vivo dendritic cell functions by conditional cell ablation. Immunol Cell Biol 2008; 86: 409-415.
59. Wilson NS, El-Sukkari D, Villadangos JA. Dendritic cells constitutively present self antigens in their immature state in vivo and regulate antigen presentation by controlling the rates of MHC class II synthesis and endocytosis. Blood 2004; 103: 2187-2195.
60. Hopper KE. Kinetics of macrophage recruitment and turnover in peritoneal inflammatory exudates induced by Salmonella or thioglycollate broth. J LeukBiol 1986; 39: 435-446.